GSK suspends GSK '052 trials due to 'microbiological finding'

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) said partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) suspended enrollment in all trials of GSK2251052 following a "microbiological finding in a small number of patients" in a Phase IIb trial to treat complicated urinary tract infections (cUTI). Anacor is working with GSK to investigate the finding, which the biotech said could take several months. ...